Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 gel for Hand and Foot Syndrome prevention
NCT07457671Phase 2Not yet recruiting
- Sponsor
- Tarian Pharma
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Onreltea in hand-foot syndrome (HFS), sponsored by Tarian Pharma. Primary endpoint: Adverse events at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Onreltea
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT07457671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457671.